The economics of the NHS cancer drugs fund

被引：0
|
作者：
Alan Maynard
Karen Bloor
机构：
[1] University of York,Department of Health Sciences
来源：
Applied Health Economics and Health Policy | 2011年 / 9卷 / 3期
关键词：
Multiple Sclerosis; Political Advantage; Cancer Drug Fund; Maximum Health Gain; Preferential Funding;
D O I：
10.2165/11585750-000000000-00000
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：137 / 138
页数：1
相关论文
共 50 条
  • [21] Faster access to Cancer Drugs Fund
    Tanday, Sanjay
    LANCET ONCOLOGY, 2012, 13 (06): : E234 - E234
  • [22] Cancer Drugs Fund of minimal benefit
    Burki, Talha Khan
    LANCET ONCOLOGY, 2017, 18 (06): : E305 - E305
  • [23] Challenges for the new Cancer Drugs Fund
    Littlejohns, Peter
    Weale, Albert
    Kieslich, Katharina
    Wilson, James
    Rumbold, Benedict
    Max, Catherine
    Rid, Annette
    LANCET ONCOLOGY, 2016, 17 (04): : 416 - 418
  • [24] Sixty seconds on ... the Cancer Drugs Fund
    Hawkes, Nigel
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 352 : i791
  • [25] A NHS PERSPECTIVE OF THE IMPACT OF THE CANCER DRUGS FUND ON ONCOLOGY DRUG USE AND OTHER HEALTH CARE RESOURCES WITHIN ENGLAND
    Kilby, S.
    VALUE IN HEALTH, 2012, 15 (04) : A232 - A232
  • [26] SUCCESS RATE OF CANCER DRUGS FUND REAPPRAISALS
    Liu, X.
    Pannett, S.
    Wallis, J.
    Bertram, J.
    VALUE IN HEALTH, 2023, 26 (12) : S321 - S321
  • [27] Moral ambivalence towards the Cancer Drugs Fund
    Epanomeritakis, Ilias Ektor
    JOURNAL OF MEDICAL ETHICS, 2019, 45 (09) : 623 - 626
  • [28] THE CANCER DRUGS FUND: PAST, PRESENT AND FUTURE
    Mildred, M.
    VALUE IN HEALTH, 2016, 19 (07) : A758 - A758
  • [29] MODELING THE IMPACT OF REFORM TO THE CANCER DRUGS FUND
    Schaffer, Karlsberg S.
    Garau, M.
    O'Neill, P.
    Bianchi, S.
    VALUE IN HEALTH, 2016, 19 (07) : A355 - A355
  • [30] The King's Fund and the NHS
    Maxwell, RJ
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1996, 55 (05): : 295 - 296
12345